[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343306-105":59,"doc-detail-343306-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rna-sequencing-identifies-lung-cancer-lineage-and-facilitates-drug-repositioning","RNA sequencing identifies lung cancer lineage and facilitates drug repositioning","","Breakthrough therapies have improved outcomes in non-small cell lung cancer, yet prospective confirmation of molecular subtypes remains insufficient. Patient datasets were downloaded from TCGA, CPTAC, and GEO, followed by downstream analyses using metagenes and 42-gene subtype classifiers. From a phenotype perspective, single-cell RNA, enhancer RNA, methylation, mutation, and copy-number variation were integrated, and preclinical platforms (CMAP, CCLE, and GDSC) were applied for drug repositioning. Three phenotypes—bronchioid, neuroendocrine, and squamoid—were validated, with poor prognosis concentrated in squamoid and neuroendocrine clusters.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rna-sequencing-identifies-lung-cancer-lineage-and-facilitates-drug-repositioning/343306/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rna-sequencing-identifies-lung-cancer-lineage-and-facilitates-drug-repositioning/343306.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What datasets and analysis strategy were used to derive lung cancer subtypes?","Question",{"text":112,"@type":113},"The study downloaded patient datasets from TCGA, CPTAC, and GEO, then performed downstream analysis using metagenes and built 42-gene subtype classifiers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which three phenotypes were verified in the work?",{"text":117,"@type":113},"The authors verified three phenotypes: bronchioid, neuroendocrine, and squamoid.",{"name":119,"@type":110,"acceptedAnswer":120},"How were therapeutic candidates explored for drug repositioning?",{"text":121,"@type":113},"Drug repositioning used preclinical models including CMAP, CCLE, and GDSC, and the study conceptually validated compounds and targets with RNA-seq and CCK-8/western blot assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343306,1790438889,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Submitted 27 May 2024  \nAccepted 2 September 2024  \nPublished 24 September 2024 Corresponding author Jianguo Sun, [sunjianguo@tmmu.edu.cn](sunjianguo@tmmu.edu.cn)[ ](sunjianguo@tmmu.edu.cn)Academic editor  \nSonia Oliveira  \nAdditional Information and Declarations can be found on page 19  \nDOI 10.7717/peerj.18159  \n Copyright 2024 Zeng et al.  \nDistributed under  \nCreative Commons CC-BY 4.0  \n1 2  \n3  \n*  \nRNA sequencing identiﬁes lung cancer lineage and facilitates drug repositioning  \nLongjin Zeng 1, *, Longyao Zhang2, *, Lingchen Li2, Xingyun Liao3, Chenrui Yin2, Lincheng Zhang 1, Xiewan Chen 1 and Jianguo Sun2  \nDepartment of Basic Medicine, Army Medical University, Chongqing, China Cancer Institute, Xinqiao Hospital, Chongqing, China  \nAfﬁliated Tumor Hospital, Department of Oncology, Chongqing, China These authors contributed equally to this work.  \nABSTRACT  \nRecent breakthrough therapies have improved survival rates in non-small cell lung cancer (NSCLC), but a paradigm for prospective conﬁrmation is still lacking. Patientdatasets were mainly downloaded from TCGA, CPTAC and GEO. We conducted downstream analysis by collecting metagenes and generated 42-gene subtype classiﬁers to elucidate biological pathways. Subsequently, scRNA, eRNA, methylation, mutation, and copy number variation were depicted from a phenotype perspective. Enhancing the clinical translatability of molecular subtypes, preclinical models including CMAP, CCLE, and GDSC were utilized for drug repositioning. Importantly, we veriﬁed the presence of previously described three phenotypes including bronchioid, neuroendocrine, and squamoid. Poor prognosis was seen insquamoid and neuroendocrine clusters for treatment-naive and immunotherapy populations. The neuroendocrine cluster was dominated by STK11 mutations and 14q13.3 ampliﬁcations, whose related methylated loci are predictive of immunotherapy. And the greatest therapeutic potential lies in the bronchioid cluster. We further estimated the relative cell abundance of the tumor microenvironment (TME), speciﬁc cell types could be reﬂected among three clusters. Meanwhile, the higher portion of immune cell inﬁltration belonged to bronchioid and squamoid, not the neuroendocrine cluster. In drug repositioning, MEK inhibitors resisted bronchioid but were squamoid-sensitive. To conceptually validate compounds/ targets, we employed RNA-seq and CCK-8/western blot assays. Our results indicated that dinaciclib and alvocidib exhibited similar activity and sensitivity in theneuroendocrine cluster. Also, a lineage factor named KLF5 recognized by inferred transcriptional factors activity could be suppressed by verteporﬁn.  \nSubjects Bioinformatics, Cell Biology, Genomics, Oncology  \nKeywords Lung adenocarcinoma, Metagene, Molecular classiﬁcation, Drug sensitivity INTRODUCTION  \nLung cancer is a heterogeneous disease that histologically consists of mainly adenocarcinoma, squamous cell carcinoma, and small cell carcinoma. Among NSCLC, adenocarcinoma is the most predominant subtype and tends to harbor driver mutations, thereby beneﬁting from targeted therapies. Meanwhile, immune checkpoint inhibitor (ICI) therapies, centering on anti-programmed death 1 (PD-1/PD-L1), become the keystone of  \nHow to cite this article Zeng L, Zhang L, Li L, Liao X, Yin C, Zhang L, Chen X, Sun J. 2024. RNA sequencing identiﬁes lung cancer lineage and facilitates drug repositioning. PeerJ 12:e18159 DOI 10.7717/peerj.18159  \nﬁrst-line therapy for driver-negative NSCLC. Histologic transformation is thought to be a molecular mechanism of therapeutic resistance, and spontaneous transformation (for example, transformation from small cell lung carcinoma to squamous cell lung carcinoma) has also been described in case reports (Davies et al., 2023; Shiba-Ishii et al., 2024) . However, there are no approved therapies for cancer lineage plasticity. Existing clinical evidence suggested that the addition of anti-PD-1/PD-L1 therapies improved prognosis inpatien","cbCaicBpT6L5fdMs","https://ap.wps.com/l/cbCaicBpT6L5fdMs","pdf",14927725,25,"English","# Abstract\n# Introduction","[{\"question\":\"What datasets and analysis strategy were used to derive lung cancer subtypes?\",\"answer\":\"The study downloaded patient datasets from TCGA, CPTAC, and GEO, then performed downstream analysis using metagenes and built 42-gene subtype classifiers.\"},{\"question\":\"Which three phenotypes were verified in the work?\",\"answer\":\"The authors verified three phenotypes: bronchioid, neuroendocrine, and squamoid.\"},{\"question\":\"How were therapeutic candidates explored for drug repositioning?\",\"answer\":\"Drug repositioning used preclinical models including CMAP, CCLE, and GDSC, and the study conceptually validated compounds and targets with RNA-seq and CCK-8/western blot assays.\"}]","RNA sequencing identifies lung cancer lineage and facilitates drug repositioning | PDF",1790050683,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ec06c9fb2983cef4eae5651dc83169c.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa1527e0b8228fdf455a3ff339e3fe94.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49a90e6c8b84a58bcaa4c8be34253986.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/956533efaa80162124f2592dea2337a9.webp",980,1268]